21/31 #TumorBoardTuesday
🏫Mini Tutorial 18🏫
CLDN18.2 CAR-T Trials:
1) Phase 1, CT041 (CLDN18.2 CAR-T) in CLDN18.2+ adv GI cancers (NCT03874897)
AKA satricabtagene autoleucel (satri-cel)
98 pts got CT041: 75% gastric/GEJ, 10% panc, 8% intestinal, 4% BTC
🏫Mini Tutorial 18🏫
CLDN18.2 CAR-T Trials:
1) Phase 1, CT041 (CLDN18.2 CAR-T) in CLDN18.2+ adv GI cancers (NCT03874897)
AKA satricabtagene autoleucel (satri-cel)
98 pts got CT041: 75% gastric/GEJ, 10% panc, 8% intestinal, 4% BTC
February 5, 2025 at 1:46 AM
21/31 #TumorBoardTuesday
🏫Mini Tutorial 18🏫
CLDN18.2 CAR-T Trials:
1) Phase 1, CT041 (CLDN18.2 CAR-T) in CLDN18.2+ adv GI cancers (NCT03874897)
AKA satricabtagene autoleucel (satri-cel)
98 pts got CT041: 75% gastric/GEJ, 10% panc, 8% intestinal, 4% BTC
🏫Mini Tutorial 18🏫
CLDN18.2 CAR-T Trials:
1) Phase 1, CT041 (CLDN18.2 CAR-T) in CLDN18.2+ adv GI cancers (NCT03874897)
AKA satricabtagene autoleucel (satri-cel)
98 pts got CT041: 75% gastric/GEJ, 10% panc, 8% intestinal, 4% BTC
In Brief: China’s drug regulator gives green light to CARsgen Therapeutics' satri-cel (satricabtagene autoleucel) for gastric cancer — the first chimeric antigen receptor (CAR) T cell therapy approved for solid tumors www.nature.com/articles/s41...
rdcu.be/ftVq1
rdcu.be/ftVq1
First CAR T for solid tumors - Nature Biotechnology
Nature Biotechnology - First CAR T for solid tumors
www.nature.com
July 15, 2026 at 2:33 PM
In Brief: China’s drug regulator gives green light to CARsgen Therapeutics' satri-cel (satricabtagene autoleucel) for gastric cancer — the first chimeric antigen receptor (CAR) T cell therapy approved for solid tumors www.nature.com/articles/s41...
rdcu.be/ftVq1
rdcu.be/ftVq1
Jiahui International Cancer Center announced Monday it started treating the first international patient with Satri-cel, the CAR-T therapy China approved June 22 for advanced gastric cancer
Satri-cel is the first CAR-T therapy approved to treat solid tumors, previously limited to blood cancers
Satri-cel is the first CAR-T therapy approved to treat solid tumors, previously limited to blood cancers
China Approves World’s First CAR T-Cell Therapy for Solid Tumors
China’s National Medical Products Administration recently approved satricabtagene autoleucel (satri-cel, CARsgen), making it the world’s first chimeric antigen receptor (CAR) T-cell therapy approved f...
www.aabb.org
July 6, 2026 at 9:57 PM
Jiahui International Cancer Center announced Monday it started treating the first international patient with Satri-cel, the CAR-T therapy China approved June 22 for advanced gastric cancer
Satri-cel is the first CAR-T therapy approved to treat solid tumors, previously limited to blood cancers
Satri-cel is the first CAR-T therapy approved to treat solid tumors, previously limited to blood cancers
Les Résultats de l’essai clinique du #Satricabtagene pour le traitement du #CancerDuPancréas ont été acceptés pour une présentation à #ESMO25
La 1ère preuve de concept au monde explorant la thérapie par cellules #CAR_T pour le traitement des #TumeursSolides
www.carsgen.com/en/news/2025...
La 1ère preuve de concept au monde explorant la thérapie par cellules #CAR_T pour le traitement des #TumeursSolides
www.carsgen.com/en/news/2025...
July 22, 2025 at 6:03 AM
Les Résultats de l’essai clinique du #Satricabtagene pour le traitement du #CancerDuPancréas ont été acceptés pour une présentation à #ESMO25
La 1ère preuve de concept au monde explorant la thérapie par cellules #CAR_T pour le traitement des #TumeursSolides
www.carsgen.com/en/news/2025...
La 1ère preuve de concept au monde explorant la thérapie par cellules #CAR_T pour le traitement des #TumeursSolides
www.carsgen.com/en/news/2025...
China Approves World’s First CAR-T Therapy for Solid Tumors: China’s National Medical Products Administration has granted approval to satricabtagene autoleucel (satri-cel), marketed as Kailimei, for patients with advanced CLDN18.2-positive and HER2-negative gastric c… https://ranked.news/1032794?u=b
June 24, 2026 at 12:07 PM
China Approves World’s First CAR-T Therapy for Solid Tumors: China’s National Medical Products Administration has granted approval to satricabtagene autoleucel (satri-cel), marketed as Kailimei, for patients with advanced CLDN18.2-positive and HER2-negative gastric c… https://ranked.news/1032794?u=b
CAR T cell therapy for solid cancer scores first approval in China
www.nature.com/articles/d41...
CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma
www.nature.com/articles/d41...
CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma
July 8, 2026 at 2:49 PM
CAR T cell therapy for solid cancer scores first approval in China
www.nature.com/articles/d41...
CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma
www.nature.com/articles/d41...
CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma
#CARSgenTherapeutics has claimed approval in #China, its home market, for satricabtagene autoleucel (#satricel), said to be the first #CARTtherapy to be approved anywhere in the world to treat a #solidtumour.
pharmaphorum.com/news/carsgen...
pharmaphorum.com/news/carsgen...
CARSgen bags world-first approval for solid tumour CAR-T
CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.
pharmaphorum.com
June 23, 2026 at 9:23 AM
#CARSgenTherapeutics has claimed approval in #China, its home market, for satricabtagene autoleucel (#satricel), said to be the first #CARTtherapy to be approved anywhere in the world to treat a #solidtumour.
pharmaphorum.com/news/carsgen...
pharmaphorum.com/news/carsgen...
China’s NMPA has approved satricabtagene autoleucel, or satri-cel, for patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy.
Link in the comments 👇
#Oncology #CART #CellTherapy
Link in the comments 👇
#Oncology #CART #CellTherapy
June 29, 2026 at 4:44 PM
China’s NMPA has approved satricabtagene autoleucel, or satri-cel, for patients with Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of therapy.
Link in the comments 👇
#Oncology #CART #CellTherapy
Link in the comments 👇
#Oncology #CART #CellTherapy
CARsgen's Satri-cel: A Breakthrough in CAR T-Cell Therapy for Cancer#China#Shanghai#CAR_T-cell_Therapy#Satri-cel#CARsgen_Therapeutics
CARsgen's Satri-cel: A Breakthrough in CAR T-Cell Therapy for Cancer
CARsgen Therapeutics reveals significant findings on satricabtagene autoleucel, or 'satri-cel', presented at key global medical venues, highlighting efficacy in advanced cancer treatments.
third-news.com
June 2, 2025 at 12:24 AM
CARsgen's Satri-cel: A Breakthrough in CAR T-Cell Therapy for Cancer#China#Shanghai#CAR_T-cell_Therapy#Satri-cel#CARsgen_Therapeutics
CARsgen's Breakthrough CAR T-Cell Therapy Shows Promise for Advanced Gastric Cancer#China#Shanghai#CARsgen#Satri-cel#G/GEJC
CARsgen's Breakthrough CAR T-Cell Therapy Shows Promise for Advanced Gastric Cancer
CARsgen Therapeutics has released significant data on its CAR T-cell therapy, satricabtagene autoleucel, for advanced gastric cancer, available on the ASCO website.
third-news.com
May 23, 2025 at 12:05 AM
CARsgen's Breakthrough CAR T-Cell Therapy Shows Promise for Advanced Gastric Cancer#China#Shanghai#CARsgen#Satri-cel#G/GEJC
CARsgen's Groundbreaking Phase II Results for Claudin18.2 CAR-T Therapy Bring Hope to Cancer Patients#China#Shanghai#CARsgen#Satri-cel#Claudin18.2
CARsgen's Groundbreaking Phase II Results for Claudin18.2 CAR-T Therapy Bring Hope to Cancer Patients
CARsgen's latest clinical trial reveals positive results for satricabtagene autoleucel, paving the way for innovative gastric cancer treatment.
third-news.com
December 30, 2024 at 2:11 PM
CARsgen's Groundbreaking Phase II Results for Claudin18.2 CAR-T Therapy Bring Hope to Cancer Patients#China#Shanghai#CARsgen#Satri-cel#Claudin18.2
Satricabtagene autoleucel mejora la supervivencia libre de progresión y general en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado CLDN18.2+ HER2- que han fallado al menos dos líneas previas de terapia firstwordpharma.com/story/7641986
Greenlit in China, CARsgen's CAR-T is first-ever approved for solid tumours | FirstWord PHARMA
Satricabtagene autoleucel, which targets CLDN18.2, was cleared for third-line gastric/gastroesophageal junction adenocarcinoma.
firstwordpharma.com
June 23, 2026 at 7:00 AM
Satricabtagene autoleucel mejora la supervivencia libre de progresión y general en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica avanzado CLDN18.2+ HER2- que han fallado al menos dos líneas previas de terapia firstwordpharma.com/story/7641986
Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer #esocsm #oncology
www.onclive.com/view/satri-c...
www.onclive.com/view/satri-c...
Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer
The NMPA of China has accepted the new drug application for satricabtagene autoleucel in pretreated gastric/GEJ cancer.
www.onclive.com
June 26, 2025 at 3:30 PM
Satri-Cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer #esocsm #oncology
www.onclive.com/view/satri-c...
www.onclive.com/view/satri-c...
Satricabtagene autoleucel (satri-cel) can improve outcomes when compared to standard therapy in patients with previously treated, advanced gastric or GEJ cancer, according to research presented at #ASCO25. #gicsm shorturl.at/Otvys
June 24, 2025 at 3:51 PM
Satricabtagene autoleucel (satri-cel) can improve outcomes when compared to standard therapy in patients with previously treated, advanced gastric or GEJ cancer, according to research presented at #ASCO25. #gicsm shorturl.at/Otvys
Thoughts on this? >> CARsgen Therapeutics Announces NDA Acceptance of Satri-cel
by China’s NMPA >> Comment below! #healthtech #AI #mhealth #industry40 #IoT
by China’s NMPA >> Comment below! #healthtech #AI #mhealth #industry40 #IoT
CARsgen Therapeutics Announces NDA Acceptance of Satri-cel
by China’s NMPA
SHANGHAI, June 25, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the …
dlvr.it
June 26, 2025 at 5:55 AM
Thoughts on this? >> CARsgen Therapeutics Announces NDA Acceptance of Satri-cel
by China’s NMPA >> Comment below! #healthtech #AI #mhealth #industry40 #IoT
by China’s NMPA >> Comment below! #healthtech #AI #mhealth #industry40 #IoT
Thoughts on this? >> CARsgen’s Satri-cel Abstract Available on ASCO
Website >> Comment below! #mhealth #industry40 #AI #healthtech #IoT
Website >> Comment below! #mhealth #industry40 #AI #healthtech #IoT
CARsgen’s Satri-cel Abstract Available on ASCO
Website
SHANGHAI, May 22, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced gastric/gastroesophageal junction …
dlvr.it
May 23, 2025 at 1:42 AM
Thoughts on this? >> CARsgen’s Satri-cel Abstract Available on ASCO
Website >> Comment below! #mhealth #industry40 #AI #healthtech #IoT
Website >> Comment below! #mhealth #industry40 #AI #healthtech #IoT
Greenlit in China, CARsgen's CAR-T is first-ever approved for solid tumours firstwordpharma.com/story/7641986
Greenlit in China, CARsgen's CAR-T is first-ever approved for solid tumours | FirstWord PHARMA
Satricabtagene autoleucel, which targets CLDN18.2, was cleared for third-line gastric/gastroesophageal junction adenocarcinoma.
firstwordpharma.com
June 22, 2026 at 10:07 PM
Greenlit in China, CARsgen's CAR-T is first-ever approved for solid tumours firstwordpharma.com/story/7641986